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Background: Thyroid diseases are the most common endocrine pathologies sec-
ond to diabetes. They have been shown to have high genetic impact, and variants 
in any of the genes involved in the metabolism of thyroid hormones have marked 
influence on the development of these diseases. 
Aim: To identify the genes that have been most involved in the development of 
thyroid pathologies by reviewing the literature with recent relevant articles. 
Materials and methods: We performed a literature search on the NCBI (National 
Center for Biotechnology Information) databases, and that of the European Bio-
informatics Institute (EMBL-EBI) using keywords related to the topic of interest). 
Results: Activation of oncogenes such as RAS, BRAF, RET/PTC and the overstimu-
lation of the PI3K/AKT pathway plays an important role in thyroid tumorigenesis. 
SLC5A5, SLC26A4, TG, TPO, DUOX2, DUOXA2 are related to hypothyroidism. Risk 
factors for Graves’ disease are associated with the presence of HLA-DR3, CTLA4, 
PTPN22, CD40, IL2RA (CD25), FCRL3, and IL23R. FOXE1 can be associated to hypo-
thyroidism and papillary thyroid cancer.
Conclusions: Thyroid diseases are polygenetic, and while there are sufficient 
pathways affected by genetic changes, and there is, to our knowledge, no gene 
that has been found to be specifically causal, and the pathology has been the 
result of the interaction of many genetic variables such as polymorphisms or mu-
tations.
BACKGROUND
Thyroid hormones (THs) are essential for the devel-
opment of mammals playing an important role in the 
immune, cardiovascular, nervous, and reproductive 
systems. In fact, it has been shown that thyroid 
dysfunction exerts effects on the female reproduc-
tive capacity causing menstrual disorders, including 
amenorrhea, oligomenorrhea and polymenorrhea.1 In 
addition, it has been known that THs also increase 
the basal metabolic rate and regulate energy ho-
meostasis, which is evident in patients with thyroid 
dysfunction. THs have also been linked to obesity 
and it has been observed that individuals with hy-
perthyroidism eat more, but lose weight, while the 
individuals with hypothyroidism eat less, but gain 
weight. Previous hypotheses have directly connected 
THs with adipose tissue, skeletal muscle, and the 
heart.2 In muscles, THs increase ATP consumption 
by acting on the Ca+ gradient between the sarco-
plasmic reticulum and the cytoplasm, among other 
mechanisms.3 
In bone development, THs also play an important 
role. In hypothyroid children, linear growth ceases 
and there is epiphyseal dysgenesis, whereas in 
children with thyrotoxicosis, linear growth increases 
and bone maturation accelerates, causing premature 
fusion of growth plaques, which causes children to 
have short stature.4
Finally, in the cardiovascular system, which has 
been the most studied in relation to the metabolism 
of THs, it has been documented that patients with 
primary thyroid dysfunction have adverse cardiovas-
cular manifestations.5 For example, hyperthyroidism 
is characterized by an increase in cardiac output 
and a reduction in peripheral vascular resistance, 
and it also increases cardiac preload as a result of 
increased blood volume, which increases the risk 
of heart damage.6
The previous physiological implications are 
only some of the many in which the THs inter-
vene; therefore, their mechanism of action has 
been widely studied over the years keeping the 
enthusiasm to know the molecular and genetic 
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bases of the damage in thyroid metabolism that 
contribute to the development of a pathology and 
consequently to a failure in the human organism. 
These explanations are not easy as the T4 and T3 
synthesis involves a complex of molecules whose 
alterations give rise to the diseases related to the 
gland.7 This review describes the most representative 
genes that have been involved in the development 
of thyroid pathologies. 
MATERIALS AND METHODS 
We did a literature search on the National Center 
for Biotechnology Information (NCBI) and on the 
European Bioinformatics Institute (EBI) databases, 
using keywords related to the topic of interest.
RESULTS 
Thyroid cancer
Homeostasis of the thyroid gland is maintained by 
the regulation of thyroid growth and differentiation, 
which occurs through a complex interaction between 
the thyroid stimulating hormone (TSH) and other 
growth factors and cytokines. There is evidence to 
support even the role of transforming growth factor 
beta 1 (TGF-β1) and epidermal growth factor (EGF) 
as a link in the regulation of thyroid differentiation 
and proliferation.8 
It should be noted that the thyroid gland is the 
most common site for epithelial hyperplasia which 
affects 15% of the adult population. In fact, it 
sporadically presents a condition called nontoxic 
Goiter’s multinodular disease, in which the gland 
usually contains well-defined nodules of variable 
size surrounded by abnormal epithelium. In relation 
to this issue, many studies have revealed evidence 
of autocrine stimulators involved in the growth and 
progression of Goiter disease, including TGF-β1.8
Thyroid cancer is one of the most common 
diseases of this gland, and is classified as papil-
lary, medullary, follicular, or anaplastic, being the 
papillary thyroid cancer (PTC) one of the malignant 
tumors with highest incidence, whose molecular 
mechanism of development is not at all clear due 
to their complexity, but what is certain is the role 
of some genetic factors that may increase the risk 
of suffering from PTC.9 In fact, it has been shown 
that activation of oncogenes such as RAS, BRAF, 
RET/PTC and the overstimulation of the PI3K/
AKT pathway plays an important role in thyroid 
tumorigenesis.8
On the other hand, simple nucleotide polymor-
phisms (SNP) have also been found in FOXE1 
and NKX2 transcription factors: in fact, FOXE1 
rs965513 and NKX2-1 rs94428 have been associated 
with differentiated thyroid cancers in Caucasian 
population.10 In relation to FOXE1 it is a thyroid-
specific transcription factor with an essential role 
in thyroid development; even more, this gene aids 
in maintaining cellular differentiation in the adult 
thyroid and recognizes sites in thyroglobulin (Tg) 
and thyroperoxidase (TPO), among others. There is 
evidence that Adamts9, Cdh1, Duox2, and S100a4 
genes increase their expression in the absence of 
FOXE1, whereas Casp4, Creld2, Dusp5, Etv5, 
Hsp5a, Nr4a2, and Tm4sf1 decrease.11 Interestingly, 
FOXE1 is involved in cleft lip and cleft palate, 
hypothyroidism and PTC, probably causing a new 
syndrome that integrates these three diseases.12
The genes coding for thyroid transcription factors 
1 and 2 (TTF1 and TTF2) have been extensively 
studied in thyroid carcinomas because they regulate 
other genes essential to thyroid function. TTF1 and 
TTF2 are expressed in different tissues, and their 
anomalies are involved in several types of cancer; 
TTF1 plays an important role in thyroid differentia-
tion and is expressed in numerous tissues and cell 
types, including the posterior pituitary tract and 
hypothalamus. On the other hand, TTF2 has also 
been found involved in embryonic development 
and thyroid formation. In fact, SNP rs944289 in 
the TTF1 gene was associated with increased risk 
of PTC, as was SNP rs96513 in the TTF2 gene, 
and were considered as susceptible genetic factors 
in Asians and Caucasians.9
Two new variants of TTF-2 (C, 200C> G) and 
(c510C> A) have also been identified in thyroid 
carcinoma. C, 200C> G was associated with lower 
expression of TPO in tumors, suggesting that this 
variant may alter the transcription of TPO, normally 
regulated by TTF-2, in addition to that, the RET 
mutation in PTC is considered the most common 
genetic alteration in this tumor.13
RET/PTC reactivity is very frequent in the PTC, 
through the activation of tyrosine kinase domain in 
the follicular cell, which in turn starts a signaling 
pathway through MAPK, leading to uncontrolled 
cell proliferation. The most commonly known 
rearrangements are RET/PTC-1 and RET/PTC-3, 
both attributed to an environmental risk factor, 
such as exposure to ionizing radiation, which has 
been previously mentioned.14 In addition, among 
the well-known environmental risks for PTC, there 
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It is noteworthy that the genetic and epigenetic 
alterations that lead to thyroid cancer are many, 
not solely those named earlier. Examples of other 
alterations leading to thyroid cancer include mu-
tation in BRAF (BRAF V600E), which leads to 
the only molecular and pathological process that 
causes failures in radioactive treatment. Mutations 
in RAS, PIK3CA, PTEN, TP53, β-catenin (CTNNB1), 
anaplastic lymphoma kinase (ALK), and dehydroge-
nase is citrate 1 (IDH1) have also been identified 
and, in addition to the latter, translocations have 
been associated in RET-PTC genes and the PAX8 
gene. Also, for the development of pathogenesis, 
modifications have been found in several cell sig-
naling pathways, including the following: MAPK; 
P13K-AKT; NFKβ and RASSF1, concluding that 
the progression of thyroid cancer is a result of 
a process of the accumulation of alterations that 
lead to secondary molecular damage involving the 
tumor cells and the microenvironment, acting in 
cooperation by amplifying and acting synergistically 
on the impact of thyroid tumorigenesis.15
Also, the RET protooncogene encodes a receptor 
tyrosine kinase (RTK) that mediates extracellular 
neurotropic signaling to intracellular transduction 
pathways including the MAPK/ERK pathway, 
which is crucial for the initiation of PTC. In fact, 
mutations in RET and RET/PTC are characteristic 
of the well-differentiated non-aggressive PTC, in 
addition to the BRAF V600E mutation, which 
have been shown to be markers of PTC in refrac-
tory thyroid cancer. It should be noted that RET/
PTC significantly suppresses PAX8 expression.16 
In fact, another arrangement of the PAX8/PPARγ 
array is found in follicular thyroid cancers (FTC) 
and eventually, in PTC. Armstrong et al. reported 
in 2014 that this arrangement was found in thy-
roid nodules and that it had a predictive value of 
100% for differentiating thyroid cancer. It should 
be noted that the PAX8/PPARγ array is formed 
through the translocation t(2; 3)(q13;25) and has 
been found in approximately 30-35% of FTC, and 
that, despite that PTC is low in frequency, it has 
been documented in follicular variants of this type 
of malignancy.17
The importance of studying transcription fac-
tors in the development of thyroid cancer is that 
these factors are critical for the development and 
function of the gland; for example, PAX8, which 
belongs to the PAX family of proteins, plays a 
critical role in the development of the thyroid to 
the point that there is evidence that mutations with 
loss-of-function in PAX8 are manifested with hy-
pothyroidism, accompanied by thyroid dysgenesis. 
The results obtained in 2016 by Rosignolo et al. 
show that the expression of PAX8 is diminished 
in tumors compared to healthy tissue.18
Regarding PAX8 expression studies, in 2015 
Lucci et al. studied the relationship between PAX8 
and neuropilin 2. In this regard, neuropilins (NRP1 
and NRP2) are transmembrane glycoproteins that 
play a central role in neuronal and blood vessel 
development, are expressed in various tissues in-
cluding endothelial cells, neurons, pancreatic islet 
cells, hepatocytes, melanocytes, osteoblasts, and 
frequently in malignant tumor cells. The authors 
found that the relationship between the two mol-
ecules was inversely proportional and that, while 
PAX8 expression decreased in tissues with thyroid 
carcinoma, that of NRP2 increased, directly influ-
encing the pathogenesis of the disease.19
PAX8 has been one of the most studied mol-
ecules in thyroid malignancies. In 2014, Filippone 
et al. studied the relationship of this transcription 
factor with WNT4, considering that WNTS genes 
are powerful regulators of cell proliferation and 
differentiation. The association between these two 
molecules comprises an interesting research point. 
The authors found that PAX8 can modulate the 
expression of WNT4 in thyroid cells and correlate 
the expression of this substance with the epithelial 
integrity of the thyroid because it is reduced in 
carcinomas. In fact, WNT4 regulation is required 
for the progression of thyroid epithelial tumors to 
a complete malignant phenotype.20
Deiodinases have also been studied in relation 
to cancer, since their expression is altered in some 
malignancies. For example, it is thought that they 
contribute to the loss-of-control in cell division 
followed by tumor development. First, it should be 
remembered that deiodinase 1 (D1) and deiodinase 
2 (D2) transform T4 into T3, while deiodinase 3 
(D3) inactivates the thyroid hormone and ends the 
action of T3. It has been observed that the expres-
sion of D1 varies depending on the pathology; 
for example, in PTC, D1 decreases or increases, 
whereas in FTC and anaplastic thyroid carcinoma 
increases. On the other hand, D2 is increased in 
FTC, in anaplastic thyroid cancer (ATC), and in 
medullary thyroid cancer (MTC), whereas in PTC, 
glioblastomas and astrocytomas is diminished.21
Meanwhile, in ATC, which is quite aggressive, 
alterations have been identified in FOXM1, which 
codes for the protein Forkhead Box M1, that be-
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longs to a family of transcription factors involved 
in the control of cell proliferation, chromosomal 
stability, and angiogenesis and is highly increased 
in non-differentiated thyroid cancer. Moreover, high 
levels of FOXM1 have been linked to a loss of 
p53 function and uncontrolled activation of the 
phosphatidylinositol-3 kinase/AKT/FOXO3a path-
way. In fact, it has been probed how the inhibition 
of FOXM1 can reduce the aggressiveness of this 
cancer type and can reduce the risk of metastasis. 
The latter has been corroborated to reveal results, 
whereas inhibiting FOXM1 not only reduces cell 
invasion, but also decreases the expression of 
FOXM1 target genes, such as cyclin B1 (CCNB1), 
polo-like kinase 1 (PLK1), and Aurora kinase B 
(AURKB), among others.22
Additionally, in PATZ1 protein, a ring of zinc 
has been recently investigated as a regulator in the 
development of cancer, the molecule is postulated 
as a tumor suppressor in thyroid carcinoma; thyroid 
malignant tissue compared to normal has reduced 
expression and is has been found that PATZ1 acti-
vates P53-dependent protective pathways, preventing 
cell proliferation, migration, and invasion.23
hypoThyroidism 
Congenital hypothyroidism (CH) is the most com-
mon endocrine disorder, with an incidence of 1 per 
3000-4000 newborns, and it can be caused by thyroid 
dysgenesis (80%) or thyroid dyshormogenesis (15%). 
The importance of this endocrine disease lies in the 
mental retardation and cognitive difficulties that can 
present in children with the disorder. Therefore, 
over the years, several studies have been designed 
to get more evidence of the molecular mechanism 
involved in the development of CH by dyshormo-
genesis, finding the following genes:
1. SLC5A5 (19p13): Encodes the sodium iodide 
(NaI) transporter and, on being altered, reduces 
entrapment of I.
2. SLC26A4 (7q31): Encodes for pendrin and affects 
the flow of I into the follicular lumen.
3. TG (8q 24): Encodes for thyroglobulin (TG) and 
affects the hormonal synthesis of thyroid hormones.
4. TPO (2q25): Encodes for thyroperoxidase (TPO) 
and affects the organization and attachment of io-
dine (I).
5. DUOX2 (5q15.3): Encodes the dual oxidase 
2 and affects the generation of H2O2, which is a 
substrate of the TPO enzyme.
6. DUOXA2 (15q15.3): Encodes for DUOX matu-
ration factor 2 and affects the generation of H2O2 
which is a substrate of the TPO enzyme.
7. IYD (6q25): Encodes for deiodinase iodotyrosine 
(DEHALI) and affects the intrathyroid process of 
recycling I.
A 2010 study by Di Cosmo et al. showed that 
reduced expression of monocarboxylate transporter 
8 (MCT8) occurs with low serum concentrations 
of T4, which gives an idea of how mutations in 
the MCT8-producing gene can alter the levels of 
THs, leading to surge of some diseases.7,24
pendred syndrome 
Pendrin is a protein transporter that exchanges 
chlorine for anions such as iodine (I) in the thyroid 
and is located on the apical membrane of the thy-
rocytes.25 It is a member of solute transport family 
SLC26A4 that includes transporters with various 
anion exchange functions.26
Mutations in SLC26A4 are responsible for the 
Pendred syndrome, an autosomal recessive disease 
characterized by sensoneural association, including 
hearing loss and a partial defect in I organification; 
80% of patients present with goiter, but only a 
minority have hypothyroidism. In 2011, Dosena et 
al. found that mutations in V239D, G334V X335, 
and I487Y FSX39 reduce pendrin activity in Israeli 
and Palestinian populations.25 In the same year, 
this same group identified other changes in Span-
ish population that gave rise to loss of function of 
pendrin, and these were P70L, P301L, and F667C, 
while V609G and D687 that caused reduction of 
significant function, different from those found in 
Middle Eastern population.27
GoiTer
Goiter, defined as an increase in the size of the 
thyroid tissue, is a continuous and important global 
health problem. It can be present in a diffuse or 
nodular manner, whereas its prevalence can range 
from 5% to 50%, although this may vary according 
to the detection method used as well as the study 
population. In nodular goiter, prevalence is higher 
in women living in areas of iodine deficiency and 
it increases with advanced age.28
In 2014, Faisal and colleagues analyzed 63 
Iraqi patients and found that mutations c1078C> 
T at position 1708 of exon 10 of the TPO gene 
and c1978C> G of exon 11 were associated with 
both toxic and non-toxic multinodular goiter and 
considering that goiter in general occurs in more 
than 10% of the population, these findings have 
an important epidemiological impact. It should 
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be recalled that in non-toxic multinodular goiter, 
an enlargement of the gland is observed without 
an increase in T4 and T3, but with an increase 
in TSH, while the toxic multinodular goiter can 
occur as Graves’ disease, toxic adenoma, and 
toxic nodular goiter, resulting in hypersensitivity 
to Immunoglobulin G (IgG) directed against TSH 
receptors. In these pathologies, T3 and T4 levels 
are high with low TSH levels. In addition to this, 
it must be taken into account that more than 50 
mutations in TPO have been identified, including 
deletions and insertions that generate an abnormal 
TPO, which triggers a production of null or re-
duced thyroid hormones and which in turn leads 
to congenital hypothyroidism, goiter, and other 
thyroid disorders.29
The development of multinodular goiter is 
associated with several factors, such as genetic 
abnormalities and iodine deficiency, among oth-
ers. Genetic abnormalities have identified a germ 
mutation of the Kelch-like ECH-protein-1 gene 
(KEAP1), which was reported as a new molecular 
cause of familial multinodular goiter.30 KEAP1 was 
originally identified as a protein associated with 
nuclear factor (erythroid-derived 2) (NRF2); this 
factor is associated with increased cell replication. 
KEAP1 also performs functions as a substrate bind-
ing protein for an ubiquitin E3-dependent complex 
ligase of Cul3, which generates the degradation of 
NRF2 by the proteasome.31 Mutations in KEAP1 
are sufficient to lead to constitutive activation of 
NRF2 by disruption in KEAP1-NRF2 interaction. 
This mutation is given by a mutant fragment in 
KEAP1 (D294T, fs * 23), which is derived from a 
KEAP1 mutant protein that is not synthesized by 
the modification. Since there is no control over 
NRF2, constitutive activation of NRF2 leads to 
the production of a multinodular goiter of familial 
origin. Two mutations have been reported for this 
gene mutation: (D294T, fs * 23) and mutation 
(R483H).29,32
Graves’ disease
Graves’ disease (GD) is an autoimmune disorder 
in which the antibodies activate the TSH receptor, 
causing hyperfunction of the thyroid gland. This 
activation stimulates follicular hypertrophy and 
consequent hyperplasia, causing an enlargement of 
the thyroid and an increase in hormone production. 
GD affects approximately 0.5% to 2% of Caucasian 
population and is a major cause of hyperthyroidism.33
A variety of polymorphisms in genes have been 
established with a direct, or with a possible, as-
sociation with the generation of GD. These genes 
have been classified into two groups. The first group 
are genes that are common to several autoimmune 
diseases, in which genes that stimulate or regulate 
the immune response can be found. These genes 
include HLA-DR3, CTLA4, PTPN22, CD40, IL2RA 
(CD25), FCRL3, and IL23R. The second group in-
cludes genes that are specific to the thyroid gland: 
TSHR and the thyroglobulin gene.34 Currently, it is 
clear that the genetic predisposition for GD is not 
only associated with a gene, but that it is presented 
by a set of genes with modest individual effects. 
Most of the previously identified loci confer a low 
risk for the disease (~1.2-1.5).35
One of the main complications of GD is oph-
thalmopathy or orbitopathy, which occurs in 25-50% 
of patients with GD Graves’ ophthalmopathy is 
characterized by the enlargement and inflammation 
of the retrobulbar content, mainly the extraocular 
muscles of the eye, with the consequent increase 
in intraocular pressure. This sign is due to a cross-
reaction of the antibodies present in GD. Anti-TSH 
receptor antibodies that although found mainly in 
the thyroid tissue, have also been found in connec-
tive tissue and adipose-tissue retrobulbar content. 
In addition, some patients may present with this 
disease with antibodies that interact with orbital 
fibroblasts, leading to the secretion and deposi-
tion of collagen and mucopolysaccharides behind 
the eyeball, resulting in an increase in intraocular 
pressure.36
Although the immunological mechanisms in 
Graves’ ophthalmopathy have been clarified, it 
is necessary to know which genetic mechanisms 
are associated with this clinical feature of GD. 
Studies have found associations between different 
genes, but it has been possible to characterize a 
gene that has been specifically associated with 
Graves’ ophthalmopathy: I-23R. This gene codes 
for a transmembrane 1 protein that binds to the 
IL23 to activate the Janus kinases, leading to the 
transcription of proinflammatory genes, including 
IL-17 and Interferon-gamma. It is already known 
that polymorphisms in IL-23R confer susceptibility 
to various autoimmune diseases, including Crohn’s 
disease, psoriasis, rheumatoid arthritis, etc.34
It has been possible to find a specific association 
of Graves’ ophthalmopathy and SNP and different 
mechanisms have been postulated:
1. SNP on IL-23R (possibly rs10889677) may 
cause receptor overexpression, leading to a differ-
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Genes and Thyroid
177Folia Medica I 2019 I Vol. 61 I No. 2
entiation of Th1 to TH17, resulting in an increase 
in the synthesis of IL-17 by these cells. This could 
subsequently lead to an increase in the release of 
TNF, causing chronic inflammation of the affected 
organ, in this case, the eyes.
2. SNP in IL-23R (possibly rs7530511) may cause 
a change in the affinity of IL-23 to its receptor, 
altering the activation of IL-23R.37
However, several studies have not found direct 
gers for their development. They represent a broad 
field of study in clinical research and genes related 
to the development of pathologies are key in the 
smooth functioning of several metabolic pathways.
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Введение: Заболевания щитовидной железы являются наиболее распростра-
нённой эндокринной патологией после диабета. Доказано, что они оказыва-
ют большое генетическое воздействие, а вариации любого из генов, участву-
ющих в метаболизме гормонов щитовидной железы, оказывают  выраженное 
воздействие на развитие этих заболеваний.
Цель: Идентифицировать гены, которые в наибольшей степени участвуют в 
развитии патологий щитовидной железы, путём обзора литературы новых 
статей.
Материалы и методы: Мы провели литературный обзор базы данных NCBI 
(Национального центра биотехнологической информации) и Европейского 
института биоинформатики (EMBL-EBI), используя ключевые слова, относя-
щиеся к разрабатываемой теме.
Результаты: Активация онкогенов, таких как RAS, BRAF, RET / PTC и избыточ-
ная стимуляция сигнального пути PI3K / AKT, играет важную роль в онкогене-
зе щитовидной железы. SLC5A5, SLC26A4, TG, TPO, DUOX2, DUOXA2 связаны 
с гипотиреозом. Факторами риска для развития Базедовой болезни (Graves’ 
disease)  являются наличие HLA-DR3, CTLA4, PTPN22, CD40, IL2RA (CD25), FCRL3 
и IL23R. FOXE1 может быть связан с гипотиреозом и папиллярным раком щи-
товидной железы.
Выводы: Заболевания щитовидной железы являются полигенетическими, 
и, хотя генетические изменения затрагивают достаточно много путей, и, на-
сколько нам известно, не существует гена, который являлся бы подтверж-
дённой специфической причиной, а патология является результатом взаи-
модействия многих генетических переменных, таких как полиморфизмы или 
мутации.
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